Global Search

Search articles, concepts, and chapters

Eye (Lond)March 200625 citations

To compare argon laser peripheral iridoplasty (ALPI) against systemic medications in treatment of acute primary angle-closure: mid-term results.

Lai J S M, Tham C C Y, Chua J K H, Poon A S Y, Chan J C H, Lam S W, Lam D S C


AI Summary

This study found no significant difference in final IOP or medication need between ALPI and systemic drugs for acute angle-closure, suggesting comparable mid-term efficacy.

Abstract

Purpose

To compare the clinical outcome of argon laser peripheral iridoplasty (ALPI) against systemic medications in treatment of acute primary angle-closure (APAC).

Methods

Consecutive patients with APAC were recruited and randomized to receive one of two treatment options: immediate ALPI or systemic acetazolamide +/- mannitol. All eyes were followed up for at least 6 months after laser iridotomy. Main outcome measures were intraocular pressure (IOP) and requirement for glaucoma medications.

Results

A total of 41 eyes (39 patients) were randomized into the ALPI group, and 38 eyes (32 patients) into the medical treatment group. There were no significant differences between the two groups in sex, age, presenting IOP, and duration of attack. Mean follow-up duration +/- SD was 15.7 +/- 5.8 months. There were no significant differences between the two groups in mean final IOP and requirement for glaucoma medications.

Conclusions

There were no statistically significant differences in mean IOP and requirement for glaucoma drugs between APAC eyes treated with ALPI and systemic medications.


MeSH Terms

AcetazolamideAcute DiseaseAgedAged, 80 and overAntihypertensive AgentsDrug Therapy, CombinationFemaleFollow-Up StudiesGlaucoma, Angle-ClosureHumansIridectomyLaser TherapyMaleMannitolMiddle AgedProspective StudiesTreatment OutcomeVisual Acuity

Is this article assigned to the wrong chapter(s)? Let us know.